Metabolic Disorder Therapeutics

Metabolic Disorder Therapeutics

Global Metabolic Disorder Therapeutics Market to Reach US$136.6 Billion by 2030

The global market for Metabolic Disorder Therapeutics estimated at US$86.2 Billion in the year 2023, is expected to reach US$136.6 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2023-2030. Diabetes Therapeutics, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$91.9 Billion by the end of the analysis period. Growth in the Hypercholesterolemia Therapeutics segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$22.7 Billion While China is Forecast to Grow at 10.3% CAGR

The Metabolic Disorder Therapeutics market in the U.S. is estimated at US$22.7 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$32.8 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Metabolic Disorder Therapeutics Market - Key Trends and Drivers Summarized

How Are Metabolic Disorder Therapeutics Addressing Growing Health Concerns?

Metabolic disorder therapeutics are playing a critical role in addressing the rising prevalence of conditions such as diabetes, obesity, and hyperlipidemia, which are becoming major global health challenges. Metabolic disorders, characterized by disruptions in normal metabolic processes, often result in severe complications like cardiovascular diseases and stroke if left untreated. Therapeutics for metabolic disorders include a range of medications, lifestyle interventions, and, in some cases, surgical procedures. The growing burden of these disorders has led to increased research and development of novel drugs that target underlying metabolic pathways to manage and treat these conditions more effectively.

What Innovations Are Shaping the Metabolic Disorder Therapeutics Market?

Recent innovations in metabolic disorder therapeutics are focusing on personalized medicine and novel drug classes. Advances in genetic research have enabled the development of targeted therapies that can address the specific genetic and metabolic profiles of individual patients. For instance, GLP-1 receptor agonists and SGLT-2 inhibitors have emerged as breakthrough treatments for diabetes, offering improved blood glucose control and additional cardiovascular benefits. Additionally, gene therapies and biologics are being explored as potential treatments for rare metabolic disorders like Gaucher disease and Pompe disease, further expanding the therapeutic options available to healthcare providers.

How Do Market Segments Define the Growth of Metabolic Disorder Therapeutics?

Disorder types include diabetes, obesity, hyperlipidemia, and rare metabolic disorders, with diabetes therapeutics holding the largest market share due to the high global prevalence of the disease. Treatment types include medications, lifestyle interventions, and surgeries such as bariatric procedures, with medications leading the market due to their accessibility and effectiveness. Geographically, North America leads the market, driven by high healthcare expenditure and a growing diabetic population, followed by Europe and the Asia-Pacific region, where rising obesity rates are contributing to market growth.

What Factors Are Driving the Growth in the Metabolic Disorder Therapeutics Market?

The growth in the metabolic disorder therapeutics market is driven by several factors, including the increasing prevalence of lifestyle-related diseases, advancements in drug development, and growing awareness of metabolic health. Rising rates of obesity, diabetes, and cardiovascular diseases are creating a significant demand for effective therapeutic solutions. Technological advancements in drug discovery and personalized medicine are enabling the development of more effective and targeted treatments. Additionally, initiatives by governments and healthcare organizations to raise awareness about metabolic health and encourage early diagnosis and intervention are further driving market growth.

Select Competitors (Total 43 Featured) -
  • AbbVie, Inc.
  • Actelion Pharmaceuticals Ltd.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Biocon Ltd.
  • BioMarin Pharmaceutical, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla, Inc.
  • CymaBay Therapeutics, Inc.
  • Eli Lilly and Company
  • Merck KgaA
  • Novo Nordisk A/S
  • Sanofi S.A.
  • Shire PLC
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Metabolic Disorder Therapeutics – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Metabolic Disorders Drives Growth in Metabolic Disorder Therapeutics Market
Technological Advancements in Gene Therapy and Personalized Medicine Strengthen Business Case for Adoption
Growing Focus on Diabetes, Obesity, and Dyslipidemia Expands Addressable Market for Metabolic Disorder Therapeutics
Expansion of Biopharmaceuticals in Treating Metabolic Disorders Fuels Market Growth
Increasing Adoption of Combination Therapies and New Drug Formulations Expands Market Opportunities
Technological Innovations in RNA-Based Therapies and Targeted Treatment Propel Market Expansion
Growing Use of Metabolic Disorder Therapeutics in Precision Medicine Expands Market Potential
Rising Adoption of Injectable and Oral Therapies for Metabolic Disorders Expands Addressable Market
Technological Advancements in Insulin Delivery Systems and GLP-1 Receptor Agonists Propel Market Growth
Increasing Focus on Regulatory Compliance and Drug Safety in Metabolic Disorder Therapeutics Drives Adoption
Rising Demand for Non-Invasive and Long-Acting Treatments Expands Market Opportunities
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Other Route of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Metabolic Disorder Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 11: World Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Metabolic Disorder Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Metabolic Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Hypercholesterolemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Hypercholesterolemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Lysosomal Storage Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Lysosomal Storage Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Lysosomal Storage Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Obesity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Inherited Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Inherited Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Inherited Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
JAPAN
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
CHINA
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
EUROPE
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Metabolic Disorder Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Metabolic Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
FRANCE
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
GERMANY
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
UNITED KINGDOM
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Spain 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Russia 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Metabolic Disorder Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Metabolic Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
AUSTRALIA
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Australia 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
INDIA
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: India 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: South Korea 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
LATIN AMERICA
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Metabolic Disorder Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Metabolic Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Argentina 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Brazil 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Mexico 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
MIDDLE EAST
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Metabolic Disorder Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Metabolic Disorder Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Iran 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Israel 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: UAE 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
AFRICA
Metabolic Disorder Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Metabolic Disorder Therapeutics by Route Of Administration - Oral, Parenteral and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Metabolic Disorder Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Route of Administrations for the Years 2014, 2024 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Metabolic Disorder Therapeutics by Disease - Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Africa 16-Year Perspective for Metabolic Disorder Therapeutics by Disease - Percentage Breakdown of Value Sales for Diabetes, Hypercholesterolemia, Lysosomal Storage Diseases, Obesity and Inherited Metabolic Disorders for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings